

Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2020

<https://marketpublishers.com/r/G7529725ECBEN.html>

Date: September 2020

Pages: 770

Price: US\$ 2,000.00 (Single User License)

ID: G7529725ECBEN

Abstracts

Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Graft Versus Host Disease - Pipeline Review, H2 2020, provides an overview of the Graft Versus Host Disease (Immunology) pipeline landscape.

Graft-versus-host disease (GVHD) is a complication that can occur after a stem cell or bone marrow transplant in which the newly transplanted donor cells attack the transplant recipient's body. Symptoms include abdominal pain or cramps, nausea, vomiting, and diarrhea, dry or irritated eyes, jaundice, shortness of breath, vaginal dryness and weight loss. Treatment includes immunosuppressants.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Graft Versus Host Disease - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Graft Versus Host Disease (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Graft Versus Host Disease (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Graft Versus Host Disease (GVHD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by

Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 1, 12, 38, 15, 3, 39, 8 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase I, Preclinical and Discovery stages comprises 1, 3, 13 and 1 molecules, respectively. Graft Versus Host Disease (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note:

Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Graft Versus Host Disease (Immunology).

The pipeline guide reviews pipeline therapeutics for Graft Versus Host Disease (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Graft Versus Host Disease (Immunology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Graft Versus Host Disease (Immunology)

therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Graft Versus Host Disease (Immunology)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Graft Versus Host Disease (Immunology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Graft Versus Host Disease (Immunology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Graft Versus Host Disease (GVHD) - Overview

Graft Versus Host Disease (GVHD) - Therapeutics Development

Graft Versus Host Disease (GVHD) - Therapeutics Assessment

Graft Versus Host Disease (GVHD) - Companies Involved in Therapeutics Development

Graft Versus Host Disease (GVHD) - Drug Profiles

Graft Versus Host Disease (GVHD) - Dormant Projects

Graft Versus Host Disease (GVHD) - Discontinued Products

Graft Versus Host Disease (GVHD) - Product Development Milestones

Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Graft Versus Host Disease (GVHD), H2 2020

Number of Products under Development by Companies, H2 2020

Number of Products under Development by Universities/Institutes, H2 2020

Products under Development by Companies, H2 2020

Products under Development by Universities/Institutes, H2 2020

Number of Products by Stage and Target, H2 2020

Number of Products by Stage and Mechanism of Action, H2 2020

Number of Products by Stage and Route of Administration, H2 2020

Number of Products by Stage and Molecule Type, H2 2020

Graft Versus Host Disease (GVHD) - Pipeline by AbbVie Inc, H2 2020

Graft Versus Host Disease (GVHD) - Pipeline by Adienne Pharma & Biotech, H2 2020

Graft Versus Host Disease (GVHD) - Pipeline by AltruBio Inc, H2 2020

Graft Versus Host Disease (GVHD) - Pipeline by Amgen Inc, H2 2020

Graft Versus Host Disease (GVHD) - Pipeline by AnaptysBio Inc, H2 2020

Graft Versus Host Disease (GVHD) - Pipeline by apceth Biopharma GmbH, H2 2020

Graft Versus Host Disease (GVHD) - Pipeline by ASC Therapeutics Inc, H2 2020

Graft Versus Host Disease (GVHD) - Pipeline by AstraZeneca Plc, H2 2020

Graft Versus Host Disease (GVHD) - Pipeline by Athersys Inc, H2 2020

Graft Versus Host Disease (GVHD) - Pipeline by Autolus Therapeutics Plc, H2 2020

Graft Versus Host Disease (GVHD) - Dormant Projects, H2 2020

Graft Versus Host Disease (GVHD) - Discontinued Products, H2 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Graft Versus Host Disease (GVHD), H2 2020

Number of Products under Development by Companies, H2 2020

Number of Products under Development by Universities/Institutes, H2 2020

Number of Products by Top 10 Targets, H2 2020

Number of Products by Stage and Top 10 Targets, H2 2020

Number of Products by Top 10 Mechanism of Actions, H2 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020

Number of Products by Top 10 Routes of Administration, H2 2020

Number of Products by Stage and Top 10 Routes of Administration, H2 2020

Number of Products by Top 10 Molecule Types, H2 2020

Number of Products by Stage and Top 10 Molecule Types, H2 2020

COMPANIES MENTIONED

AbbVie Inc

Adienne Pharma & Biotech

AltruBio Inc

Amgen Inc

AnaptysBio Inc

apceth Biopharma GmbH

ASC Therapeutics Inc

AstraZeneca Plc

Athersys Inc

Autolus Therapeutics Plc

Bellicum Pharmaceuticals Inc

Biocon Ltd

Biogen Inc

BioIncept LLC

BioTheryX Inc

BlueRock Therapeutics

Boryung ViGenCell Inc

Bristol-Myers Squibb Co

Capricor Therapeutics Inc

Cellect Biotechnology Ltd

Collective BioTherapy Inc
Cellix Bio Pvt Ltd
CheckPoint Immunology Inc
Clinigen Group Plc
CSL Ltd
CTI BioPharma Corp
Cytodyn Inc
Cytpeutics Pte Ltd
Daewoong Pharmaceutical Co Ltd
Dualogics Corp
Educell doo
Eli Lilly and Co
enGene Inc
Enlivex Therapeutics Ltd
Evive Biotech
ExCellThera Inc
F. Hoffmann-La Roche Ltd
Fate Therapeutics Inc
Fujifilm Holdings Corp
Genentech USA Inc
GigaGen Inc
GlaxoSmithKline Plc
Glia LLC
Humanigen Inc
iCELL Biotechnology Co Ltd
Implacate
Immune Modulation Inc
ImmuneTarget Inc
Imstem Biotechnology Inc
Incyte Corp
Inspyr Therapeutics Inc
Jazz Pharmaceuticals Plc
JN Biosciences LLC
Kadmon Corp LLC
Kalytera Therapeutics Inc
Kamada Ltd
Kiniksa Pharmaceuticals Ltd
Kymab Ltd
LG Chem Ltd

MaaT Pharma
Machavert Pharmaceuticals LLC
Magenta Therapeutics Inc
Mallinckrodt Plc
Medexus Pharmaceuticals Inc
Medicenna Therapeutics Corp
Mediolanum farmaceutici SpA
Medsenic SAS
Mereo Biopharma Group Plc
Mesoblast Ltd
Millennium Pharmaceuticals Inc
MitoImmune Therapeutics Inc
NapaJen Pharma Inc
Neovii Pharmaceuticals AG
Nurix Therapeutics Inc
OncolImmune Inc
OSE Immunotherapeutics
Panorama Research Inc
Pfizer Inc
Platinum Biotech (Beijing) Co Ltd
Pluristem Therapeutics Inc
Precision Biosciences Inc
REGiMMUNE Corp
SCM lifescience Co Ltd
Seattle Genetics Inc
Secura Bio Inc
Seres Therapeutics Inc
Shenzhen Chipscreen Biosciences Co Ltd
STERO Biotechs Ltd
StingInn LLC
Suzhou Connect Biopharmaceuticals Ltd
Suzhou Zelgen Biopharmaceutical Co Ltd
Syndax Pharmaceuticals Inc
Synthetic Biologics Inc
Takeda Pharmaceutical Co Ltd
Targazyme Inc
TCF GmbH
TeralImmune Inc
TGV Laboratories Inc

United BioPharma Inc
Vault Pharma Inc
Visterra Inc
Xenikos BV
Xenothera SAS
XL-protein GmbH

I would like to order

Product name: Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2020

Product link: <https://marketpublishers.com/r/G7529725ECBEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G7529725ECBEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970